US Kidney Biopsy Market Overview:
As per MRFR analysis, the US Kidney Biopsy Market Size was estimated at 616 (USD Million) in 2023. The US Kidney Biopsy Market Industry is expected to grow from 646.8(USD Million) in 2024 to 1,059.76 (USD Million) by 2035. The US Kidney Biopsy Market CAGR (growth rate) is expected to be around 4.591% during the forecast period (2025 - 2035).
Key US Kidney Biopsy Market Trends Highlighted
The US Kidney Biopsy Market is experiencing several notable trends driven by advancements in technology and an increasing prevalence of chronic kidney diseases. One of the key market drivers is the rising incidence of kidney-related disorders, prompting healthcare providers to turn to biopsy procedures for accurate diagnosis and effective treatment options. As awareness regarding kidney health continues to grow, there is a notable push for early detection of kidney diseases, further emphasizing the role of biopsies. Additionally, the integration of advanced imaging techniques and needle biopsy methods enhances the safety and accuracy of procedures, leading to more favorable patient outcomes.Opportunities for growth in the US market can be explored through the development of innovative biopsy devices and techniques, including minimally invasive options that reduce recovery time and complications associated with traditional methods. Further advancements in precision medicine offer potential for personalized treatment plans, which can greatly influence patient care and improve chronic disease management. Recent trends indicate a shift towards outpatient procedures for kidney biopsies, facilitated by advancements in imaging modalities and growing preferences for less invasive treatments. Furthermore, collaborations among healthcare providers, academic institutions, and research organizations are increasingly focusing on refining biopsy protocols and improving patient outcomes.With an emphasis on dietary education and lifestyle modifications alongside medical interventions, the US healthcare system is also prioritizing preventive approaches to kidney health, which might indirectly increase the demand for kidney biopsy procedures in the long term. These trends collectively point towards a dynamic and evolving landscape in the US Kidney Biopsy Market, with significant implications for healthcare providers and patients alike.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
US Kidney Biopsy Market Drivers
Rising Prevalence of Kidney Diseases
The increasing incidence of kidney diseases in the United States significantly drives the US Kidney Biopsy Market Industry. According to the Centers for Disease Control and Prevention, approximately 37 million adults in the US are estimated to have chronic kidney disease (CKD), which is about 15% of the adult population. As renal diseases continue to rise, the need for accurate diagnosis requiring kidney biopsies is also expected to increase. The National Kidney Foundation and other organizations advocate for earlier detection and intervention strategies, promoting kidney biopsies as a crucial tool in managing CKD and other renal dysfunctions.This growing patient demographic presents a compelling opportunity for advancements in biopsy methodologies and technologies, further solidifying the importance of biopsies in healthcare settings across the nation.
Technological Advancements in Biopsy Techniques
Technological advancements in kidney biopsy techniques are fueling growth in the US Kidney Biopsy Market Industry. Innovations such as ultrasound-guided biopsies and needle technologies have improved the accuracy and safety of biopsy procedures. The introduction of automated devices and imaging techniques has been reported to reduce complications associated with traditional methods. The American Urological Association has highlighted that ultrasound guidance can increase the success rate of kidney biopsies by up to 90%, thereby encouraging more medical professionals to adopt these advanced techniques.As technology continues to evolve, it is expected that more healthcare facilities will integrate these innovations, enhancing patient outcomes related to kidney health.
Increase in the Geriatric Population
The increasing geriatric population in the United States is another significant driver for the US Kidney Biopsy Market Industry. As per the Administration for Community Living, the percentage of the population aged 65 and older is projected to reach approximately 23% by 2060. This demographic is more susceptible to various health issues, including kidney diseases, necessitating precise diagnostic techniques such as kidney biopsies. With programs like the Affordable Care Act promoting preventive care for seniors, the accessibility of kidney biopsies is likely to increase in the coming years.The growing need for effective management of kidney-related diseases in older adults positions kidney biopsies as a crucial component of the healthcare system.
US Kidney Biopsy Market Segment Insights:
Kidney Biopsy Market End-User Insights
The US Kidney Biopsy Market offers significant insights into its End-User segmentation, which primarily includes Hospitals and Clinics, Urology Centers, Tertiary Care Centers, and other specialized facilities. Hospitals and Clinics generally account for a major share of the kidney biopsy procedures performed, driven by their comprehensive facilities and access to advanced diagnostic technologies. They are integral in managing patient care, particularly in urban settings where the demand for early detection of kidney-related disorders is crucial.Urology Centers focus specifically on urological conditions and play a vital role in kidney biopsies by offering specialized expertise, thus ensuring accurate diagnoses and improved patient outcomes. These centers are increasingly becoming vital as more patients seek targeted care from specialists. Tertiary Care Centers, known for their advanced medical technologies and specialized treatment protocols, are significant players in the market as they often handle complex cases requiring expert evaluation. Other facilities comprise outpatient clinics and diagnostic centers, which provide alternative options for patients seeking kidney biopsies, contributing to the overall accessibility of these services.This diverse array of end-users demonstrates the multifaceted nature of the US health care landscape related to kidney biopsy, highlighting the importance of each segment in meeting growing patient demands and fulfilling the need for precise diagnosis in kidney health. The increasing prevalence of chronic kidney diseases and advancements in biopsy techniques further enhance the importance of these facilities, creating opportunities for growth and development across all End-User categories in the market. Emphasizing the capabilities of each segment reveals how they contribute to the broader landscape of the US Kidney Biopsy Market, significantly influencing market dynamics and driving innovation in procedures and patient care.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Kidney Biopsy Market Indication Insights
The US Kidney Biopsy Market is a crucial part of the healthcare landscape, specifically concerning the management and diagnosis of various kidney-related disorders. Within this market, the Indication segment highlights significant areas such as Kidney Failure, Kidney Transplant, Hematuria, and Proteinuria, each playing a vital role in understanding and treating kidney diseases. Kidney Failure is a critical area that drives the need for biopsies due to the complexity of diagnosis and treatment decisions involved for nephrologists. Kidney Transplant cases are often accompanied by biopsy procedures to ensure optimal post-surgical outcomes and to monitor for rejection.Meanwhile, Hematuria and Proteinuria are essential indicators of kidney issues that prompt health practitioners to perform biopsies for precise assessment. The increasing incidence of these conditions, influenced by factors like diabetes and hypertension, further underscores the importance of the Indication segment. As awareness of kidney health escalates in the US, the relevance of these indications in guiding treatment strategies and enhancing patient outcomes continues to grow, ultimately propelling advancements in the US Kidney Biopsy Market.
Kidney Biopsy Market Type Insights
The US Kidney Biopsy Market segmentation by Type reveals critical insights into the methodologies employed for kidney diagnostics. Key segments include Percutaneous Biopsy and Surgical Biopsy, each playing a pivotal role in the overall market. Percutaneous Biopsy is increasingly favored due to its minimally invasive nature, leading to shorter recovery times and reduced patient discomfort, which resonates well with the growing patient-centric healthcare approach in the United States. On the other hand, Surgical Biopsy continues to maintain significance in complex cases where detailed tissue analysis is required, showcasing its importance in comprehensive diagnostics.The rising prevalence of kidney diseases and disorders, largely attributable to diabetes and hypertension, propels the demand for efficient biopsy techniques. Furthermore, advancements in imaging technologies enhance the precision of these procedures, bolstering market growth. Overall, the US Kidney Biopsy Market continues to evolve with a focus on improving patient outcomes and procedural efficiencies, presenting both challenges and opportunities for healthcare providers and practitioners in this critical aspect of renal health management.
US Kidney Biopsy Market Key Players and Competitive Insights:
The US Kidney Biopsy Market is characterized by an array of sophisticated medical technologies and services aimed at enhancing the diagnosis and treatment of kidney-related ailments. This market has been experiencing considerable growth due to the increasing prevalence of chronic kidney diseases and the rising need for accurate diagnostic procedures. The competitive landscape is shaped by various key players who are innovating and expanding their product offerings to capture a larger share of this specialized market. The competitive insights reveal that companies are focusing not only on improving the accuracy and efficiency of biopsy procedures but also on enhancing patient experiences and outcomes. Advancements in imaging techniques and minimally invasive procedures are also becoming significant trends that drive competition within this sector.Exact Sciences holds a strategic position in the US Kidney Biopsy Market, focusing on developing innovative diagnostic solutions tailored to the needs of kidney disease patients. The company's strength lies in its commitment to research and development, which propels the introduction of cutting-edge technologies that facilitate non-invasive and minimally invasive biopsy procedures. Exact Sciences has garnered a reputation for reliable diagnostics, bolstered by its rigorous testing protocols and partnerships with healthcare providers. Their approach emphasizes both accuracy and patient-centered care, making them a formidable competitor in this market landscape. Exact Sciences' ability to address the growing demand for kidney diagnostics through technological advancements strengthens its position, allowing for continuous growth and expansion in the US market.Hologic is another significant player in the US Kidney Biopsy Market, known for its robust portfolio of diagnostic and imaging solutions that cater specifically to nephrology. The company has established a strong presence through its innovative products and services, which not only include advanced biopsy systems but also comprehensive imaging solutions that enhance procedural efficiency. Hologic's strengths lie in its cutting-edge technology and commitment to precision medicine, bolstering its market presence among healthcare professionals. The company has actively pursued mergers and acquisitions to expand its capabilities and reach within the kidney biopsy segment, enhancing its service offerings and market position. Their focus on addressing the specific needs of kidney disease diagnostics, coupled with a strong distribution network, further reinforces Hologic’s competitive advantage in the US market.
Key Companies in the US Kidney Biopsy Market Include:
Exact Sciences
Hologic
BioRad Laboratories
GRAIL
Laboratory Corporation of America
Roche Diagnostics
Crown Bioscience
Genomic Health
Abbott Laboratories
Thermo Fisher Scientific
Mayo Clinic
Siemens Healthineers
Fisher Scientific
Quest Diagnostics
Becton Dickinson
US Kidney Biopsy Market Industry Developments
Recent developments in the US Kidney Biopsy Market reflect significant advancements and competitive dynamics among key players. Companies like Exact Sciences, Hologic, and BioRad Laboratories are actively innovating within this space, focusing on novel biomarker discovery and enhanced diagnostic techniques. The market continues to see a growing interest in minimally invasive procedures, significantly benefitting patients and healthcare providers alike. In terms of mergers and acquisitions, there has been notable activity, including Roche Diagnostics acquiring a strategic technology firm in September 2023 to bolster their diagnostic offerings in kidney-related diseases, and Laboratory Corporation of America acquiring a promising biotechnology startup in August 2023 to enhance laboratory capabilities. Over the past few years, the US Kidney Biopsy Market has also experienced increased investment, fueled by a rise in chronic kidney diseases, heightening demand for groundbreaking diagnostic solutions. Companies such as Thermo Fisher Scientific and Quest Diagnostics are expanding their portfolio to include advanced genomic analysis technologies, further driving market growth. Overall, the US Kidney Biopsy Market showcases robust activity and innovation, positioning itself for significant future developments in the healthcare industry.
US Kidney Biopsy Market Segmentation Insights
Kidney Biopsy Market End-User Outlook
Hospitals & Clinics
Urology Centers
Tertiary Care Centers
Others
Kidney Biopsy Market Indication Outlook
Kidney Failure
Kidney Transplant
Hematuria
Proteinuria
Kidney Biopsy Market Type Outlook
Percutaneous Biopsy
Surgical Biopsy
Report Scope:
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 616.0(USD Million) |
| MARKET SIZE 2024 | 646.8(USD Million) |
| MARKET SIZE 2035 | 1059.76(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.591% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Exact Sciences, Hologic, BioRad Laboratories, GRAIL, Laboratory Corporation of America, Roche Diagnostics, Crown Bioscience, Genomic Health, Abbott Laboratories, Thermo Fisher Scientific, Mayo Clinic, Siemens Healthineers, Fisher Scientific, Quest Diagnostics, Becton Dickinson |
| SEGMENTS COVERED | End-User, Indication, Type |
| KEY MARKET OPPORTUNITIES | Increased prevalence of kidney diseases, Advancements in biopsy technologies, Growing demand for minimally invasive procedures, Rising awareness of early diagnosis, Expansion of diagnostic imaging services |
| KEY MARKET DYNAMICS | Growing prevalence of kidney diseases, Advancements in biopsy techniques, Increasing healthcare expenditure, Rising geriatric population, Technological innovations in imaging |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Kidney Biopsy Market is expected to be valued at 646.8 million USD in 2024.
By 2035, the US Kidney Biopsy Market is anticipated to reach a value of 1,059.76 million USD.
The expected CAGR for the US Kidney Biopsy Market from 2025 to 2035 is 4.591%.
Hospitals and clinics dominate the US Kidney Biopsy Market, valued at 350.0 million USD in 2024.
Urology Centers are valued at 180.0 million USD in the US Kidney Biopsy Market for the year 2024.
Tertiary Care Centers are projected to reach a market value of 128.0 million USD by 2035.
Major players in the US Kidney Biopsy Market include Exact Sciences, Hologic, BioRad Laboratories, and Laboratory Corporation of America, among others.
'Others' segment is expected to be valued at 36.8 million USD in the US Kidney Biopsy Market for the year 2024.
The US Kidney Biopsy Market offers growth opportunities driven by increasing incidences of kidney diseases and advancements in biopsy techniques.
Growing demand for accurate diagnostic procedures and rising healthcare expenditure are key drivers contributing to the growth of the US Kidney Biopsy Market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
